We are international
Donate
TEXT SIZE   
   back

Pomalidomide News: Promising Results Increase Chances of Early Drug Approval
The results of a study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone in relapsed/refractory patients show both improved progression free survival and overall survival.
10.23.12

The results of study MM-003, comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone have been released by Celgene International Sari (Boudry, Switzerland).  This Phase III, multicenter, randomized, open label trial indicates that the pomalidomide arm of the study shows both improved progression free survival (PFS) and overall survival (OS).  Professor Jesus San Miguel, Head of the Department of Hematology at the University of Salamanca in Spain and principal investigator for the study, was clearly very encouraged by the results indicating that: “The survival results in this study build on earlier observations of high response rates for pomalidomide and dexamethasone in multiple myeloma.”

The benefit in patients who relapsed on or were refractory to (having ultimately progressed on) at least 2 prior therapies, including both lenalidomide (Revlimid®) and bortezomib (Velcade®) is impressive and would seem to meet the FDA criteria for filling an “unmet need” for refractory/relapsing myeloma patients.  When the FDA recently cancelled the planned ODAC hearing for pomalidomide (see prior blog), there were questions about what that might mean.  However, today’s announcement really increases the likelihood of favorable review of pomalidomide by the FDA and potential early approval.  The pomalidomide combination has, in addition, been submitted to the EMA (regulatory agency) in Europe with expectation of a decision in 2013. The EMA and the FDA have regular joint conference calls to review joint submissions and share data.

For more information, see Celgene's press release "Pomalidomide Demonstrated Significant Progression-Free Survival and Overall Survival Advantages in Phase III Study of Heavily Pre-Treated Myeloma Patients".


 related videos
 related articles
ASCO 2013: Dr. Jagannath - Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM): MM-002 phase II age subgroup analysis.
"Understanding Health Disparities in Cancer: The Case of Multiple Myeloma"
Understanding Adherence to Oral Cancer Therapy
Understanding Serum Free Light Chain and Serum Heavy/Light Chain Assays
ASCO 2013: Dr. Jagannath - Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM): MM-002 phase II age subgroup analysis.
Best of ASH 2013: What Patients Need to Know
BLACK SWAN RESEARCH INITIATIVE™ DONOR LEVELS
BLACK SWAN RESEARCH INITIATIVE™ MEDIA CONTACT
BRAZIL WORKSHOP
California Support Group Leader’s Testimony Makes Huge Difference
Cancer Awareness Bracelets
Dr. Brian Durie, Chairman of the International Myeloma Foundation, Honored by Mayo Clinic With Distinguished Alumni Award
IMF Nurse Leadership Board (NLB) Survivorship Care Plan for Mutliple Myeloma published in the Clinical Journal of Oncology Nursing.
IMF's 8th Annual Comedy Celebration: Big Laughs, Big Success
International Myeloma Foundation (IMF)
Flow Workshop Presentations
July 18-19, 2014
International Myeloma Foundation Mission Statement
Mensajero del Mieloma - Otoño 2012 - #903
Michael and Robin Tuohy of Connecticut Help to Pass State Oral Parity Bill
Raise Your Voice Web Series
Sign up TODAY for Advocacy Training Two-Part Online Series!
Supreme Court Upholds Affordable Care Act
The International Myeloma Foundation Applauds Wisconsin Gov. Scott Walker for Signing SB 300 (The Cancer Treatment Fairness Act) into Law